Gilead's $3B Truvada will face generics a year early. Can Descovy still win over its patients?

9th May 2019 Uncategorised 0

Gilead’s big-selling HIV drug Truvada wasn’t supposed to see generic competition until 2021, or so executives have been saying. But in its latest quarterly filing, the company said Teva can roll its copy next year, giving Gilead less time to woo patients over to its newer drug Descovy.

More: Gilead's B Truvada will face generics a year early. Can Descovy still win over its patients?
Source: fierce